Skip Navigation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (18)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Li, S.
Right arrow Articles by Dudczak, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Li, S.
Right arrow Articles by Dudczak, R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 14:1274-1277, 2003
© 2003 European Society for Medical Oncology

Original Paper

Imaging gastrointestinal tumours using vascular endothelial growth factor-165 (VEGF165) receptor scintigraphy

S. Li1,+, M. Peck-Radosavljevic2, O. Kienast1, J. Preitfellner1, G. Hamilton3, A. Kurtaran1, C. Pirich1, P. Angelberger4 and R. Dudczak1

1 Department of Nuclear Medicine, 2 Department of Internal Medicine IV, Division of Gastroenterology and Hepatology, and 3 Department of Surgery, University of Vienna, Vienna; 4 Austrian Research Center, Seibersdorf, Austria

Received 1 April 2003; accepted 23 April 2003

Background:

Recent studies have shown that vascular endothelial growth factor (VEGF) receptor is overexpressed in vascular endothelial cells of various human tumours as well as in human tumour cells. The aim of this study was to evaluate the usefulness of scanning with VEGF165 labeled with 123I for tumor localisation in patients with gastrointestinal tumours.

Patients and methods:

Human recombinant VEGF165 was radiolabelled with 123I by electrophilic radioiodination using the chloramine T method. [123I]VEGF165 was administered intravenously [mean dose 184 ± 18 MBq (<=130 pmol; <=5 µg) per patient] to 18 patients with gastrointestinal tumours. Dynamic acquisition was initiated immediately after administration and carried out until 30 min post-injection. Whole body images were done in anterior and posterior views at various time points. All patients underwent single-photon emission tomography imaging 1.5 h post-injection. Scanning with [123I]VEGF165 was compared with computed tomography and magnetic resonance imaging.

Results:

Intravenous injection of [123I]VEGF165 did not cause any side-effects. Binding of [123I]VEGF165 to primary tumours and metastases was visible shortly after injection. In patients with pancreatic adenocarcinomas, primary tumours were visualised in seven of nine, lymph node metastases in three of four, liver metastases in three of six and lung metastases in one of three. Cholangiocarcinomas were visualised by imaging in one of two patients. Hepatocellular carcinomas were visible by imaging in two of four patients. [123I]VEGF165 scans were weakly positive in one patient with abdominal schwannoma and in one patient with peritoneal carcinosis.

Conclusions:

These results indicate that scanning with [123I]VEGF165 can visualise gastrointestinal tumours and metastases expressing receptors for VEGF165. [123I]VEGF165 receptor scintigraphy may be useful for visualisation of tumour angiogenesis.

Key words: angiogenesis, gastrointestinal, receptors, scintigraphy, tumours, VEGF


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JNMHome page
W. Cai and X. Chen
Multimodality Molecular Imaging of Tumor Angiogenesis
J. Nucl. Med., June 1, 2008; 49(Suppl_2): 113S - 128S.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
A. R. Hsu and X. Chen
Advances in Anatomic, Functional, and Molecular Imaging of Angiogenesis
J. Nucl. Med., April 1, 2008; 49(4): 511 - 514.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
G. Mariani, P. A. Erba, and A. Signore
Receptor-Mediated Tumor Targeting with Radiolabeled Peptides: There Is More to It than Somatostatin Analogs
J. Nucl. Med., December 1, 2006; 47(12): 1904 - 1907.
[Full Text] [PDF]

Home page
 JNMHome page
C. Chan, J. Sandhu, A. Guha, D. A. Scollard, J. Wang, P. Chen, K. Bai, L. Lee, and R. M. Reilly
A Human Transferrin-Vascular Endothelial Growth Factor (hnTf-VEGF) Fusion Protein Containing an Integrated Binding Site for 111In for Imaging Tumor Angiogenesis
J. Nucl. Med., October 1, 2005; 46(10): 1745 - 1752.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
J. C. Miller, H. H. Pien, D. Sahani, A. G. Sorensen, and J. H. Thrall
Imaging Angiogenesis: Applications and Potential for Drug Development
J Natl Cancer Inst, February 2, 2005; 97(3): 172 - 187.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. Van Den Bossche and C. Van de Wiele
Receptor Imaging in Oncology by Means of Nuclear Medicine: Current Status
J. Clin. Oncol., September 1, 2004; 22(17): 3593 - 3607.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. Radiol.Home page
G J R Cook
Oncological molecular imaging: nuclear medicine techniques
Br. J. Radiol., December 1, 2003; 76(suppl_2): S152 - S158.
[Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.